TRIB2 and lung carcinoma: TRIB2 has been shown to contribute to tumorigenesis in lung cancer through the downregulation of C/EBPα [27] and TRIB2 direct interaction with AKT has been shown to be an important mechanism that contributes to resistance to anti-cancer drug therapy [28].